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Osteosarcoma is the most common primary malignant 
bone tumor and the treatment of osteosarcoma requires a 
combined approach of surgery and systemic chemothera-
py. Since the introduction of chemotherapy into the multi-
modal treatment regimen of osteosarcoma, the prognosis 
has impressively improved, with long-term survival being 
achieved by two-thirds of all patients.
1-4) Th  e  disease-free 
survival rates have been reported to be between 55-75% in 
the previous large and multicentric studies.
5-8)
Th   e purpose of this study is to evaluate the disease-
free survival (DFS) and overall survival (OS) of patients 
with stage IIB osteosarcoma at a single institution for 20 




We reviewed 167 patients who were diagnosed as hav-
ing osteosarcoma and who were treated at our institution 
from January 1988 to November 2008. We retrospectively 
selected 117 patients from among the 167 who met the 
following criteria: 1) Enneking stage IIB; 2) wide or radi-
cal excision of tumor; 3) chemotherapy at our institution; 
and 4) complete medical records with the last follow-up. 
Background: The purpose of this study is to evaluate the disease-free survival (DFS) and overall survival (OS) of patients with 
stage IIB osteosarcoma at a single institution for 20 years and to compare the results according to the chemotherapy protocols.
Methods: From Jan 1988 to Nov 2008, 167 patients with osteosarcoma were treated at our hospital and among them, 117 pa-
tients (67 males and 50 females) with stage IIB osteosarcoma were evaluable. Their mean age was 22.6 years (range, 8 months to 
71 years). Seventy-eight cases underwent the modiﬁ  ed T10 (M-T10) protocol (group 1), 23 cases underwent the T20 protocol (group 
2) and 16 cases underwent the T12 protocol (group 3). The DFS and OS were calculated and compared according to the chemo-
therapy protocols.
Results: At a mean follow-up of 78.9 months, 63 patients were continuously disease-free (63/117), 6 patients were alive after 
having metastatic lesions, 7 patients died of other cause and 41 patients died of their disease. The 5- and 10-year OS rates were 
60.2% and 44.8%, respectively and the 5- and 10-year DFS rates were 53.5% and 41.4%, respectively. There was no signiﬁ  cant 
difference of the OS and DFS between the chemotherapy protocols (p = 0.692, p = 0.113).
Conclusions: At present, we achieved success rates close to the internationally accepted DFS and OS. We were able to achieve 
the higher survival rates using the M-T10 protocol over the 20 years. However, there was no signiﬁ  cant difference of results be-
tween the chemotherapy protocols. We think the M-T10 protocol will achieve more favorable results in the near future.
Keywords: Osteosarcoma, Chemotherapy protocol, Long-term survival rate49
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Th   e patients with metastatic disease at the time of diagno-
sis were excluded from this study. Th   e demographics and 
characteristics of the patients and lesions are reported in 
Table 1.
The simple radiographs and magnetic resonance 
imaging of the affected whole bone were obtained, and 
chest computed tomography and Tc99 bone scintigraphy 
of the whole body were used for the metastasis work-up. 
The diagnosis of osteosarcoma was always confirmed on 
the histologic slides of tumor tissue obtained from an open 
biopsy and from the resected specimens. Th  e  pathological 
investigation that was done at other centers was repeated 
by pathologists at our hospital and we obtained another 
biopsy for a suspicious diagnosis. The surgical stage was 
assessed according to the system of Enneking et al.
9)
Th   e status of the patient with regard to the disease 
at the time of the fi  nal follow-up was recorded as continu-
ously disease free (CDF), no evidence of disease at present, 
but recurrence or metastasis in the past (NED), died of 
disease (DOD) or died of other causes (DOC). 
Chemotherapy
The patients who received chemotherapy at our hospi-
tal underwent three types of protocols during the study 
period (Table 2). All the protocols included neoadjuvant 
chemotherapy. Before May 1994, 16 patients underwent 
the T12 protocol, which Rosen et al.
3,10,11) have described. 
From June 1994 to April 1999, 45 patients underwent the 
modifi  ed T10 (M-T10) protocol, which has been accurate-
ly described in several papers.
3,12) From May 1999 to April 
2001, 22 patients underwent the T20 protocol and from 
May 2001 to November 2008, 33 patients underwent the 
M-T10 protocol again. Th   ese protocols have been reported 
in detail elsewhere.
3,10-13)
Th   e adjuvant chemotherapy was based on the histo-
logical response to the primary chemotherapy. Good re-
sponder patients received the same drugs that were given 
preoperatively, whereas salvage chemotherapy was done 
for the poor responders. Patients with pulmonary metas-
tases received thoracotomy at least once, except for those 
with too many lung lesion to excise or those who were in 
such poor condition that they could not tolerate the proce-
dure. Of the 117 included patients, 78 patients underwent 
the M-T10 protocol (group 1), 23 patients underwent the 
T20 protocol (group 2) and 16 patients underwent the T12 
protocol (group 3).
Surgery
Th   e type of surgery (amputation and limb salvage surgery) 
as well the type of reconstruction aft  er limb salvage were 
Table 1. Characteristics of Our Patients (n = 117)
Characteristics Values
Age at diagnosis, median (range) 22.6 yr (8 mo-71 yr )
Male : Female 67 : 50
Histologic subtype
   Osteoblastic   81 (69.2)
   Chondroblastic   18 (15.4)
   Fibroblastic   14 (12.0)
   Telangiectactic     4 (3.4)
Primary lesion
   Distal femur   49 (41.9)
   Proximal tibia   38 (32.5)
   Humerus    11 (9.4)
   Proximal femur     3 (2.6)
   Proximal ﬁ  bula     4 (3.4)
   Distal tibia     2 (1.7) 
   Distal radius     1 (0.8) 
   Hand     1 (0.8)
   Patella     1 (0.8)
   Pelvis     5 (4.3)
   Scapula     2 (1.7)
Surgery
   Amputation     7 (6.0)
   Limb-salvage surgery 110 (94.0)
       Endoprosthetic reconstruction   53 (45.2)
           Only endoprosthesis   49 (41.9)
           Autograft-prosthesis composite     4 (3.4)
       Biologic reconstruction   49 (41.9)
           Extracorporeally-irradiated (ECI) autograft   19 (16.2)
           Allograft   12 (10.3)
           Temporary spacer    12 (10.3)
           Pasteurization     4 (3.4)
           ECI autograft with vascularized ﬁ  bular 
              bone graft     1 (0.8)
           Vascularized ﬁ  bular bone graft     1 (0.8)
       Wide excision without reconstruction     8 (6.8)
           Proximal ﬁ  bulectomy     3 (2.6)
           Total scapulectomy     2 (1.7)
           Type I pelvic resection     2 (1.7)
           Extraskeletal osteosarcoma excision     1 (0.8)
Values are presented as number (%).50
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chosen depending on the tumor location and extension, 
the involved neurovascular structures, the skeletal ma-
turity and the presence of complicating factors such as 
displaced pathologic fractures or an infected biopsy site. 
The time span covered by this study was very long (21 
years) and so the surgical techniques for local treatment 
may have changed, but it was always considered manda-
tory that the preoperative staging assured the possibility 
of achieving wide surgical margins and preserving a limb 
that could at least be partially functional aft  er resection.
Statistical Analysis
Th   e DFS & OS were major focuses of this study. DFS was 
calculated from the date of biopsy until systemic metas-
tasis, local recurrence or death from toxicity, and other 
causes of death were considered adverse event. OS was 
calculated from the date of the diagnostic biopsy until 
death or the last follow-up visit. Th   e survival curves were 
calculated according to the Kaplan-Meier method and 
they were compared by means of the log-rank test (SPSS 
ver. 12.0, SPSS Inc., Chicago, IL, USA). Th   e calculated sur-
vival rates were compared according to the chemotherapy 




At a mean follow-up of 79.8 months, the age distribution 
was from 8 months old to 71 years old, and the mean age 
was 22.6 years. Th   ere were 67 males and 50 females. Forty-
five patients (38.4%) developed pulmonary metastases. 
Of the patients with pulmonary metastasis, there were 27 
males and 18 females and their mean age was 27.0 years 
(range, 7 to 61 years) and the mean follow-up duration 
was 85.3 months (range, 5 to 122 months).
Toddler patients were rare, with only 2 patients 
(1.7%) presenting in the first 5 years of life. About 9 pa-
tients (7.6%) were in the first decade of life, 66 (56.4%) 
were in the second, 16 (13.6%) were in the third, 13 (11.1%) 
were in the fourth, 6 (5.1%) were in the fi  ft  h and 5 (4.2%) 
were above the sixth. 
Of the 117 selected patients, the defi  nite histologic 
diagnoses were osteoblastic osteosarcoma (n = 81), chon-
droblastic osteosarcoma (n = 18), fi  broblastic osteosarco-
ma (n = 14) and telangiectactic osteosarcoma (n = 4). Th  e 
primary lesions were located in the distal femur (n = 49), 
proximal tibia (n = 38), humerus (n = 11), pelvis (n = 5), 
proximal femur (n = 3), proximal fi  bula (n = 4), distal tibia 
(n = 2), scapula (n = 2), hand (n = 1), distal radius (n = 1), 
and patella (n = 1) (Table 1).
Sixty-three patients were CDF, 6 patients were NED, 
Table 2. Protocols of Neoadjuvant Chemotherapy
Protocol Period No. of patients Preoperative treatment Postoperative treatment
T12 1988-1994 16 HDMTX-CDDP-ADR-BCD Good responders: HDMTX-BCD 
Poor responders: ADR-CDDP
Modiﬁ  ed-T10  1994-1999 45 HDMTX-CDDP-ADR Good responders: HDMTX-CDDP-ADR 
Poor responders: HDMTX-IFOS-ADR
T20 1999-2001 22 HDMTX-CDDP-ADR-IFOS Good responders: HDMTX-CDDP-ADR-IFOS 
Poor responders: Raise MTX dose to 15 gm
Modiﬁ  ed-T10  2001-2008 33 HDMTX-CDDP-ADR Good responders: HDMTX-CDDP-ADR 
Poor responders: HDMTX-IFOS-ADR
Table 3. Oncologic Results 
Oncologic result Speciﬁ  c history No. (%)
Continuously disease-free 63 (53.8)
Died of disease 41 (35.0)
Only lung met 35
Lung, brain met   3 
Local recurrence, lung met   2 
Liver   1 
Died of other causes    7 (6.0)
Nadir   3
Hypovolemia   2
Sepsis   1
Renal failure   1
No evidence of disease at 
  present, but recurrence or 
  metastasis in the past
Lung metastectomy   6 (5.2)51
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7 patients were DOC, and 41 patients were DOD (Table 3). 
Sixty-three patients (53.8%) remained continuously event-
free. There were 46 systemic metastasis (39.3%), 1 local 
recurrence (0.8%), 3 died from chemotherapy toxicity, 3 
died due to postoperative hypovolemia and 1 died due to 
renal failure.
Surgery
For the 117 patients with no initial misdiagnosis, the 
surgery after neoadjuvant chemotherapy included 7 am-
putations and 110 limb-salvage procedures. The fifty-
three patients who had endoprosthetic reconstruction 
were managed with only endoprosthetic reconstruction (n 
= 49) and an autograft-prosthesis-composite (n = 4). Of 
the forty-nine patients who underwent biological recon-
struction, they were managed with an extracorporeally-
irradiated (ECI) autograft   (n = 19), an allograft   (n = 12), 
a temporary spacer (n = 12), pasteurization (n = 4), ECI 
with a vascularized fi  bular bone graft   (VFBG) (n =1) and 
only VFBG (n = 1). Of the eight patients who underwent 
wide excision without reconstruction, they underwent 
total scapulectomy (n =2), proximal fibulectomy (n = 3) 
and type I pelvic resection (n = 2) and 1 had extraskeletal 
osteosarcoma of the hand (Table 1).
DFS and OS
Th   e 5-year DFS was 53.5% and the 5-year OS was 60.2%. 
Th   e 10-year DFS was 41.4% and the 10-year OS was 44.8% 
(Fig. 1). As illustrated in Table 4, the 5-year DFS of each 
group was 59.8% in group 1, 36.3% in group 2 and 43.7% 
in group 3, and the 5 year OS was 64.6% in group 1, 50.0% 
in group 2 and 50.0% group 3, respectively (Figs. 2 and 3). 
Th   ere were no signifi  cant diff  erences in the 5-year DFS (p 
Fig. 1. Disease-free survival (DFS) and overall survival (OS) of the 117 
patients.
Table 4. Disease-Free Survival (DFS) and Overall Survival (OS) according to the Groups
No. 5-yr DFS (%) p-value 5-yr OS (%) p-value
Group 1 78 59.8 0.113 64.6 0.692
Group 2 22 43.7 50.0
Group 3 16 36.3 50.0
Fig. 3. Kaplan-Meier overall survival curves according to the che-
motherapy protocols.
Fig. 2. Kaplan-Meier disease-free survival curves according to the che-
mo therapy  protocols.52
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= 0.113) and the OS (p = 0.692) between the groups treat-
ed with diff  erent neoadjuvant chemotherapy; those treated 
with the group 1 chemotherapy protocol (the M-T10 pro-
tocol) had a higher rate of 5-year DFS and 5-year OS than 
those treated with the remaining 2 protocols. 
DISCUSSION
The results of surgery alone as a treatment for osteosar-
coma have not been satisfactory. Th   e 5-year DFS rate aft  er 
treatment by surgery alone has been reported to be only 
12%.
14) Neoadjuvant chemotherapy was introduced in 
1978.
3) Th   e purposes of neoadjuvant chemotherapy are the 
destruction of the primary tumor cells and the eradication 
of micrometastasis. Today, using a multi-modal approach 
consisting of neoadjuvant systemic polychemotherapy fol-
lowed by local surgical therapy and then adjuvant chemo-
therapy, long-term, DFS can be achieved in 60-70% of the 
patients.
However, the DFS rates of 55-65%, which were 
achieved 10 years ago, have not been improved despite 
strenuous eff  ort.
5,6,8) Th   e study of an Italian group, which 
evaluated patients with no metastasis at presentation, 
had a total survival rate of 70% and a DFS rate of 59% at 
10 years. A Germany-Austria-Switzerland study group 
reported a 10-year total survival rate of 59.8% and a 10- 
year DFS rate of 48.9%. Th   e results we achieved at a single 
institute are close to these rates. 
Our results of DFS and OS showed a slight lower 
rate than the other internationally data. Th  e  fi  rst reason for 
these results was a short minimum follow-up period. Bacci 
et al.
1) reported higher DFS and OS for patients who were 
followed for at least 5 years. Bielack et al.
6) reported 5-, 10- 
and 15-year event-free survival rates of 52.8%, 49.4%, and 
48.3%, respectively. These results are comparable to our 
results, but our results for over 10-year DFS were lower 
than the results that Bielack et al.
6) reported. To determine 
accurate results, a long-term follow-up period and at least 
the 5-year follow-up data are needed. 
Th   e second reason that our DFS and OS showed a 
slight lower rate was that we did not limit the subjects to 
those with only osteosarcoma of an extremity. We includ-
ed patients with osteosarcoma of the axial skeleton in the 
study. The OS of patients with osteosarcoma of the axial 
skeleton such as pelvis, spine and scapula is considered to 
be poorer than that of patients with extremity osteosar-
coma.
15) For these reasons, we suggest our results for the 5- 
and 10-year DFS and OS were underestimated.
The current standard protocol of a three-drug 
chemotherapy regimen using cisplatin, doxorubicin and 
high-dose methotrexate provides about 70% long-term 
disease-free survival for osteosarcoma patients without 
metastasis.
16) Even with their potential to cause severe, life-
threatening toxicity, doxorubicin and methotrexate have 
been successfully applied as chemotherapy drugs for the 
treatment of osteosarcoma.
17,18) In one study on osteosar-
coma chemotherapy, vincristine, bleomycin and dactino-
mycin were all proven to be ineffective.
19,20) Our results 
also proved the ineff  ectiveness of the above three drugs. 
Th  e  benefi  t of adding ifosfamide, a fourth agent that 
is generally accepted as being active against the disease, 
to the regimens of doxorubicin, cisplatin and high-dose 
methotrexate remains to be confirmed.
21,22) The Italian, 
Scandinavian and COSS groups have used all four drugs 
together with promising results.
21,23,24) However, the addi-
tion of ifosfamide did not result in a survival advantage in 
a large, randomized North American study.
25) Subsequent-
ly, the addition of cisplatin and ifosfamide to doxorubicin 
and methotrexate has been able to significantly improve 
the clinical results.
21,26) Th   e M-T10 protocol is now used as 
the chemotherapy protocol for osteosarcoma patients in 
our institution. The ongoing challenges include tailoring 
chemotherapy to the individual risk of relapse and devel-
oping biologically driven treatment strategies. 
The limitation of this study is the relatively small 
number of patients compared with the other studies about 
long-term results of osteosarcoma. Th   e study design rep-
resents another limitation, since this was a single institute 
retrospective study and no randomization chemotherapy 
protocol was followed during the span of the study. 
In conclusion, the 5-year OS rate of osteosarcoma 
increased from 50% to more than 65% during the study 
period. Our results for the DFS and OS were close to the 
internationally accepted rates. We could achieve the higher 
survival rates using the M-T10 protocol over the 20 years. 
However, there was no signifi  cant diff  erence of the results 
between the chemotherapy protocols. We think that the 
M-T10 protocol could achieve more favorable results in 
the near future. 
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